– UK, Worthing – Allergy Therapeutics (LON: AGY), the fully integrated commercial biotechnology company specializing in allergy vaccines, today announced the appointment of David Ball to its Board as an independent Non-Executive Director with immediate effect.
“I am delighted to announce David’s appointment and welcome him to the Board at this exciting and positive time for the Company. David has an impressive breadth of executive and financial markets experience, and we look forward to his contributions to the Board and oversight of our Audit and Risk Committee.” said Board Chairman, Peter Jensen.
David Ball has also joined the Audit and Risk Committee as Chair.
About David Ball
David Ball has over 25 years of experience in financial markets, including 15 years as an equity portfolio manager and partner with Tudor Investment Corporation. He is a chartered accountant and holds undergraduate and postgraduate degrees in engineering from Cambridge University.
David Ball said: “I am delighted to be joining the Board of Allergy Therapeutics and look forward to working with my fellow Board members and the wider team to further develop Allergy’s leading position in the sector.”
About Allergy Therapeutics
Allergy Therapeutics is an international commercial biotechnology company, headquartered in the UK, focussed on the treatment and diagnosis of allergic disorders, including aluminium-free immunotherapy vaccines that have the potential to cure disease. The Group sells proprietary and third-party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries.
For more: https://www.allergytherapeutics.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.